Romania
Tuberculosis profile
Population  2013 22 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.2 (1.2–1.2) 5.4 (5.4–5.5)
Mortality (HIV+TB only) 0.089 (0.061–0.12) 0.41 (0.28–0.57)
Prevalence  (includes HIV+TB) 27 (13–45) 123 (60–209)
Incidence  (includes HIV+TB) 19 (17–22) 87 (79–101)
Incidence (HIV+TB only) 0.52 (0.47–0.6) 2.4 (2.2–2.8)
Case detection, all forms (%) 82 (71–90)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.8 (1.8–4.2) 11 (8–15)
MDR-TB cases among notified pulmonary
TB cases
300 (190–440) 410 (300–540)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 8 085   2 196
Pulmonary, clinically diagnosed 2 472   346
Extrapulmonary 2 303   121
       
Total new and relapse 15 523    
Previously treated, excluding relapses 1 188    
Total cases notified 16 711    
Among 15 523 new and relapse cases:
695 (4%) cases aged under 15 years; male:female ratio: 2.0
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 4 737 (59%) 2 263 (59%) 7 000
Laboratory-confirmed RR-/MDR-TB cases     627
Patients started on MDR-TB treatment     650
TB/HIV 2013 Number (%)
TB patients with known HIV status 9 688 (58)
HIV-positive TB patients 265 (3)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 239 (90)
HIV-positive TB patients on antiretroviral therapy (ART) 244 (92)
HIV-positive people screened for TB 183  
HIV-positive people provided with IPT 155  
Treatment success rate (%)
New and relapse cases registered in 2012 85
Previously treated cases, excluding relapse, registered in 2012 45
HIV-positive TB cases, all types, registered in 2012 60
RR-/MDR-TB cases started on second-line treatment in 2011 26
XDR-TB cases started on second-line treatment in 2011 18
Laboratories 2013  
Smear (per 100 000 population) 0.5
Culture (per 5 million population) 22.5
Drug susceptibility testing (per 5 million population) 10.9
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 18
% Funded domestically 44%
% Funded internationally 19%
% Unfunded 36%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-30 Data: www.who.int/tb/data